2015-09: A Phase II Randomized, Open-label Study of Anti-SLAMF7 mAb During Maintenance Therapy Versus Standard Maintenance Therapy in Gene Expression Profiling (GEP)- Defined Low Risk Multiple Myeloma Patients With High Risk Cytogenetic Abnormalities
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 06 Apr 2017 Planned End Date changed from 1 Mar 2023 to 1 May 2023.
- 06 Apr 2017 Planned primary completion date changed from 1 Mar 2023 to 1 May 2023.